| 1 | ROB BONTA |
|----|---|
| 2 | Supervising Deputy Attorney General |
| 3 | |
| 4 | Deputy Attorney General State Bar No. 234540 |
| 5 | 600 West Broadway, Suite 1800 San Diego, CA 92101 |
| 6 | P.O. Box 85266 San Diego, CA 92186-5266 |
| 7 | Telephone: (619) 738-9465 Facsimile: (619) 645-2061 |
| 8 | Attorneys for Complainant |
| 9 | |
| 10 | BEFORE THE MEDICAL BOARD OF CALIFORNIA |
| 11 | DEPARTMENT OF CONSUMER AFFAIRS |
| 12 | STATE OF CALIFORNIA |
| 13 | In the Matter of the Accusation Against: Case No. 800-2021-079384 |
| 14 | FRIEDERIKE CARLA VON LINTIG, M.D. A C C U S A T I O N |
| 15 | 2815 S Grade Road Alpine, CA 91901 |
| 16 | Physician's and Surgeon's Certificate No. A 84284, |
| 17 | Respondent. |
| 18 | - Respondent. |
| 19 | |
| 20 | <u>PARTIES</u> |
| 21 | 1. Reji Varghese (Complainant) brings this Accusation solely in his official capacity as |
| 22 | the Executive Director of the Medical Board of California, Department of Consumer Affairs |
| 23 | (Board). |
| 24 | 2. On or about August 8, 2003, the Medical Board issued Physician's and Surgeon's |
| 25 | Certificate No. A 84284 to Friederike Carla Von Lintig, M.D. (Respondent). The Physician's an |
| 26 | Surgeon's Certificate was in full force and effect at all times relevant to the charges brought |
| 27 | herein and will expire on November 30, 2024, unless renewed. |
| 28 | . /// |
| | 1 |

(FRIEDERIKE CARLA VON LINTIG, M.D.) ACCUSATION NO. 800-2021-079384

(FRIEDERIKE CARLA VON LINTIG, M.D.) ACCUSATION NO. 800-2021-079384

- 10. On or about November 6, 2019, Patient A, a then twenty-four-year-old female, was booked into a criminal detention facility. During her initial intake at the facility, Patient A admitted to regular use of heroin, alcohol, and Xanax,² with her last use being approximately two hours prior to booking. Patient A identified her prior withdrawal symptoms to include tremors or shakes, sweating, headache, and nausea or vomiting, but denied any prior seizure activity. An onsite pregnancy test revealed positive results. Patient A was determined to be fit to continue the booking process and a standard nursing protocol was ordered, which consisted of a daily prenatal vitamin and ondansetron³ 4 mg twice daily for five days. Patient A was advised to drink fluids as tolerated and to notify staff if her condition worsens. Patient A was not placed on a polysubstance withdrawal protocol.
- 11. Between on or about November 6, 2019, and on or about November 10, 2019, while housed in mainline housing, Patient A was witnessed by other inmates and staff to be experiencing repeated intractable emesis, at times self-induced. Patient A was encouraged to continue to drink fluids as tolerated.
- 12. On or about November 10, 2019, at approximately 10:18 a.m., Patient A was seen by C.G., M.D. (Dr. C.G.) for the first time. Patient A complained of intractable vomiting, reported that she was approximately five weeks pregnant with a desire for termination, and was withdrawing from heroin and alcohol. Dr. C.G. obtained Patient A's blood pressure, temperature, and pulse, but otherwise did not conduct a physical examination at that time or anytime thereafter. Dr. C.G. noted Patient A was orthostatic, but alert and conversant. Dr. C.G. diagnosed Patient A with intrauterine pregnancy with vomiting and mild dehydration. Dr. C.G. ordered Patient A to be transferred to the Medical Observation Unit (MOB) for observation and oral hydration,

² Xanax (brand name for alprazolam) is a Schedule IV controlled substance pursuant to Health and Safety Code section 11057, subdivision (d), and a dangerous drug pursuant to section 4022 of the Code. It is a benzodiazepine medication used to treat anxiety and panic disorder.

³ Ondansetron (brand name Zofran) is a medication used to prevent nausea and vomiting. It is a dangerous drug pursuant to section 4022 of the Code.

⁴ Orthostatic is a form of low blood pressure that happens when standing up from sitting or lying down.

prescribed Zofran 8 mg three times daily, and referred Patient A to Planned Parenthood for termination.

- 13. On or about November 10, 2019, at approximately 11:21 a.m., Dr. C.G. noted that Patient A had not yet received treatment for withdrawal since her admission to the detention facility four days earlier, and ordered Vistaril⁵ 50 mg twice daily.
- 14. On or about November 10, 2019, Patient A was admitted to the MOB and was housed with multiple other inmates. Throughout the day, Patient A was witnessed by other inmates and staff to be experiencing repeated intractable emesis, at times self-induced. At some point that evening, Patient A was transferred to an isolation unit within the MOB.
- 15. On or about November 11, 2019, at approximately 8:40 a.m., Patient A was seen by L.R., R.N. (Nurse L.R.). Patient A complained of repeated fainting and vomiting and was advised to refrain from self-induced vomiting.
- Respondent for the first time. Respondent noted Patient A had been admitted to the MOB for "fainting spells," but understood medical staff had a high suspicion of Patient A staging her "fainting spells" for second gain purposes. Respondent incorrectly noted in Patient A's chart that she had finished treatment for alcohol and heroin withdrawal. Patient A complained of vomiting all of her food and drinks and requested IV hydration. Respondent did not obtain Patient A's vital signs and did not perform and/or document a physical examination at that time. Respondent instructed Patient A to rest, to ingest only small amounts of food and drink at a time, and to refrain from self-induced vomiting. At the conclusion of the visit, Respondent ordered Patient A to be on a full liquid diet for three days and to be discharged that day from the MOB back to mainline housing. Respondent did not at that time, or any time thereafter, refer Patient A to the emergency department for treatment of her active substance use withdrawal during pregnancy,

⁵ Vistaril (brand name for hydroxyzine pamoate) is an antihistamine with anticholinergic (drying) and sedative properties used as a sedative to treat anxiety and tension. It is a dangerous drug pursuant to section 4022 of the Code.

did not order a stat comprehensive blood panel, complete blood count, urinalysis, or electrocardiogram, and did not order IV fluids.

- 17. On or about November 11, 2019, at approximately 1:00 p.m., Patient A was being transported from the MOB back to mainline housing. While seated in a wheelchair outside her isolation cell, Patient A's body suddenly stiffened with her head resting on the back of the chair and her legs dangling on the floor. Patient A's eyes were open and her pupils were slightly dilated but reactive to light. Patient A was not verbally responsive and was not following commands. Patient A was placed back into her cell onto a mattress on the floor, given oxygen, and an urgent call for medical personnel was initiated.
- 18. On or about November 11, 2019, at approximately 1:03 p.m., Dr. C.G. responded to Patient A's isolation cell. Upon her arrival, Dr. C.G. spoke with nursing staff and ordered Patient A be given Ativan⁶ 1 mg by mouth.
- 19. On or about November 11, 2019, at approximately 1:06 p.m., Respondent responded to Patient A's isolation cell, spoke with nursing staff and Dr. C.G., and then assumed the care of Patient A.⁷ Respondent performed a physical examination of Patient A and noted her hands and feet were very cold to the touch but the remainder of her body felt warm. Respondent further noted Patient A to be awake and alert, had no visible tongue bite, supple neck, and no urinary incontinence. Patient A's initial oxygen saturation was measured to be 87% and a subsequent reading was unable to be obtained despite Respondent's efforts. Respondent further noted Patient A had "normal" vital signs, but did not document any vital signs in the patient's chart. Respondent's assessment was that Patient A had not experienced a "true seizure," but she was unable to exclude a medical cause for the patient's weakness and fainting spells. Respondent did not perform a complete physical or neurological examination of Patient A, did not refer Patient A to the emergency department, and did not order a stat comprehensive blood panel, complete blood

⁶ Ativan (brand name for lorazepam) is a Schedule IV controlled substance pursuant to Health and Safety Code section 11057, subdivision (d), and a dangerous drug pursuant to section 4022 of the Code. It is a benzodiazepine medication used to treat anxiety.

⁷ Shortly after Respondent assumed the care of Patient A, Dr. C.G. left the area and never returned.

count, urinalysis, electrocardiogram, or IV fluids. At the conclusion of the visit, Respondent ordered Patient A to remain in the MOB for observation, with a plan to recheck in the morning and discharge her back to mainline housing at that time.

- 20. On or about November 11, 2019, at approximately 3:15 p.m., staff witnessed Patient A sitting backwards on the toilet when her body stiffened with her head resting on the floor and her feet in the air. A deputy and Nurse L.R., responded to Patient A's cell and placed Patient A back onto her mattress on the floor. Shortly thereafter, Patient A came out of her stiffness and began responding to questions. Nurse L.R. called the medical clinic and relayed to R.I., R.N. (Nurse R.I.), a request to have Respondent return to the MOB to evaluate Patient A. Nurse R.I. relayed the message to Respondent. Sometime thereafter, Respondent watched Patient A in her isolation cell for a few moments through a video monitor, but did not at that time, or anytime thereafter, return to the MOB to evaluate Patient A.
- 21. On or about November 11, 2019, at approximately 8:06 p.m., Patient A was found non-responsive in her cell and was subsequently pronounced dead as a result of complications of polysubstance abuse with early intrauterine pregnancy.
- 22. Respondent committed gross negligence in her care and treatment of Patient A, which included, but was not limited to, the following:
 - A. Failing to appropriately medically manage a pregnant patient in active withdrawal on or about November 11, 2019, at approximately 9:40 a.m.;
 - B. Failing to perform an appropriate physical exam, work-up, and plan of treatment for a patient with an undiagnosed acute medical condition on or about November 11, 2019, at approximately 1:00 p.m.; and
 - C. Failing to perform an appropriate physical exam, work-up, and plan of treatment for a patient with an undiagnosed acute medical condition on or about November 11, 2019, at approximately 3:15 p.m.

///

⁸ Respondent did not issue and/or document more specific orders regarding how frequent Patient A should be "observed" or what that observation should entail.

SECOND CAUSE FOR DISCIPLINE

(Repeated Negligent Acts)

23. Respondent has further subjected her Physician's and Surgeon's Certificate No. A 84284 to disciplinary action under sections 2227 and 2234, as defined by section 2234, subdivision (c), of the Code, in that she committed repeated negligent acts in her care and treatment of Patient A, as more particularly alleged in paragraphs 9 through 22(C), above, which are hereby incorporated by reference and realleged as if fully set forth herein.

THIRD CAUSE FOR DISCIPLINE

(Failure to Maintain Adequate and Accurate Records)

| 24. Respondent has further subjected her Physician's and Surgeon's Certificate No. |
|---|
| A 84284 to disciplinary action under sections 2227 and 2234, as defined by section 2266, of the |
| Code, in that Respondent failed to maintain adequate and accurate records regarding her care and |
| treatment of Patient A, as more particularly alleged in paragraphs 9 through 21, above, which are |
| hereby incorporated by reference and realleged as if fully set forth herein. |
| |

///

///

///

26 | /// 27 | ///

28 | ///

2.7

28

PRAYER

WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged, and that following the hearing, the Medical Board of California issue a decision:

- 1. Revoking or suspending Physician's and Surgeon's Certificate No. A 84284, issued to Respondent Friederike Carla Von Lintig, M.D.;
- 2. Revoking, suspending or denying approval of Respondent Friederike Carla Von Lintig, M.D.'s authority to supervise physician assistants and advanced practice nurses;
- 3. Ordering Respondent Friederike Carla Von Lintig, M.D., to pay the Board the costs of the investigation and enforcement of this case, and if placed on probation, the costs of probation monitoring; and
 - 4. Taking such other and further action as deemed necessary and proper.

OCT 0 3 2023

DATED:

REJI VARGHESE

Executive Director

Medical Board of California

Department of Consumer Affairs

State of California Complainant

SD2022304669 84088130.docx

Ç